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Application of alginate-microencapsulated therapeutic cells is a promising approach for diseases that
require a local and constant supply of therapeutic molecules. However most conventional alginate
microencapsulation systems are associated with low mechanical stability and protrusion of cells which is
associated with higher surface roughness and limits their clinical application. Here we have developed a
novel multilayer encapsulation system that prevents cells from protruding from capsules. The system was
tested using a therapeutic protein with anti-tumor activity overexpressed in mammalian cells. The cell
containing core of the multilayer capsule was formed by flexible alginate, creating a cell sustaining
environment. Surrounded by a poly-L-lysine layer the flexible core was enveloped in a high-G alginate
matrix that is less flexible and has highermechanical stability, which does not support cell survival. The cells
in the core of the multilayer capsule did not show growth impairment and protein production was normal
for periods up to 70 days in vitro. The additional alginate layer also lowered the surface roughness compared
to conventional cell containing alginate-PLL capsules. Our system provides a solution for two important,
often overlooked phenomena in cell encapsulation: preventing cell protrusion and improving surface
roughness.
I
mmunoisolation of cells for implantation purposes is based on enveloping the cells in a biocompatible and
semipermeable membrane that allows diffusion of essential nutrients and therapeutic molecules but prevents
deleterious effects of the humoral and cellular part of the host immune system1,2. The technique is proposed for
the delivery of cell based therapeutics where local and minute-to-minute release of the active molecule is desired
for effective treatment. Encapsulation of living cells for the release of biological therapeutics is under investigation
for a variety of diseases such as diabetes3, neurological diseases4–7, and cancer8–10.
A commonly applied technology of immunoisolation is microencapsulation of therapeutic cells in spherical
beads made of alginate polymers11 using different encapsulation techniques like electrostatic bead generator, jet
cutter, vibrating nozzle, and coaxial air driven droplet generator12. Spherical beads are often preferred over discs
or tube like structure because of the favorable surface-to-volume ratio which facilitates nutrition of the cells and
the release of therapeutic agents11. Another argument to favor microcapsules is the relative small size that allows
for transplantation in many sites without interference with the receiving organ11. The latter is an important
consideration for example in the treatment of brain tumors, where implantation of microencapsulated cells
producing anti-tumor agents has been proposed as an effective approach to delete remnants ofmalignant cells13,14.
Invasive brain tumor cells are impossible to recognize and eliminate during surgery and are a major cause of
morbidity.
Microcapsules that are being proposed for diseases such as for the treatment of brain tumors should meet a
number of requirements. A key feature in designing immunoisolating microcapsules is avoiding protrusion of
cells from capsules.Most conventional alginate encapsulation systems do notmeet this prerequisite, as protrusion
of cells is more the rule than an exception (figure 1). Protrusion of cells is associated with rejection and fibrotic
responses followed by necrosis of the therapeutic cells, which ultimately leads to graft failure15. Another danger is
that the therapeutic cells based on cell lines may form tumors themselves when they leak out of the capsules. This
is a major safety hurdle preventing the application of cell encapsulation technology in the clinic. Therefore cell
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Alginate is the most commonly applied polymer for cell encap-
sulation, due to its biocompatibility, ease of processing and heat
stable nature16,17. Alginate is a polysaccharide of linear copolymers
of (1–4) glycosidically linked a L-guluronic acid (G) and its C-5
epimere, b D-mannuronic acid (M) residues. The relative amount
of the two uronic acid monomers as well as their sequential arrange-
ment along the polymer chain differs widely. The uronic acid resi-
dues are distributed along the polymer chain in a pattern of binary
blocks: G-G blocks, M-M block, or M-G blocks. Based on the com-
position of G and M residue, alginate is classified as high-G alginate
(G content $ 60%), intermediate-G alginate (G content in range of
40–60%), and low-G alginate (G content # 40%). The composition
as well as the molecular weight of alginate determines the physio-
chemical properties of the capsules, which also affect cell function18.
The aim of the present study was to develop a novel multilayer
capsule which overcomes protrusion of cells and high surface rough-
ness while maintaining efficacy of secretion of the therapeutic pro-
tein. In the novel system we applied alginate with different
mechanical stabilities to facilitate growth of the cells in the core of
the capsules but to kill cells that might escape from the capsule and
invade the host (figure 2a).
Results
To prevent cell protrusion from alginate capsules, we applied differ-
ent types of alginate to produce gels with different mechanical
stability19. The 3.4% intermediate-G alginate beads gelled in
100 mMCaCl2 solution had a rigidity of 9.47 6 1.61 g and an elasti-
city of 7.99 6 0.76 s. The 2% high-G alginate beads were more rigid
(11.05 6 0.77 g) and less elastic (9.12 6 0.57 s) than 3.4% inter-
mediate-G alginate beads. A too rigid environment will lead to dereg-
ulation of cellular metabolism and protein synthesis, eventually
leading to cell death. The tests were performed with a mammalian
cell lines (BHK cells), as these cells are often applied in preclinical
models for the release of therapeutic agents9,20. BHK cells were encap-
sulated in alginates with two different rigidities and elasticities after
which functional survival was studied. The methodology to make
multilayer capsules is described in the method section (figure 2b).
Long-term survival and protection of outgrowth of BHK cells in
different alginate types. We then investigated the survival of the
cells at different periods of time in 3.4% intermediate-G alginate
capsules and 2% high-G alginate beads. Cell survival was
monitored on a weekly basis and images were acquired on day 1,
7, 14, 21, and day 28 as shown in figure 3. Within 1st week, BHK cells
encapsulated in 3.4% intermediate-G alginate started to grow
without obstruction and formed cellular clusters. By day 28, these
capsules were completely filled with cells. This was very different in
the more rigid 2% high-G alginate capsules. Cell growth was
impaired when compared to the cells in the 3.4% intermediate-G
alginate. On day 28 most of the cells encapsulated in 2% high-G
alginate were dark and necrotic indicating that 2% high-G alginate
hampers cell survival.
Cell behavior in the multilayer system. To determine whether the
multilayer system caused an impairment in cell survival, we studied
the viability of BHK cells in the multilayer system in comparison to
the conventional 3.4% intermediate-G alginate APA capsules.
Viability studies were done on at day 1, 7, 14, 21, 28, 35, 49, 56, 63,
and day 70. As shown in figure 4a cell survival and growth in both the
control 3.4% intermediate-G alginate APA capsules and in the
multilayer capsules steadily increased from day 1 to day 70. Cells
in the multilayer capsules grew slower. The multilayer capsules were
completely filled by day 49, whereas the 3.4% intermediate-G
alginate APA capsules were already filled by day 28. Live dead
quantification of cells shows approximately 85% of live cells in
both conventional and multilayer capsules at any given time point.
Outgrowth of cells in the control capsules was observed by day 14.
This was associated with cell growth in the culture flask. In the
multilayer capsule cultures we did not observe cells in the flask.
Cells in multilayer capsules started to migrate to the outer layer as
of day 28, but were trapped effectively and died (figure 4b). To
summarize we show that multilayer capsules prevent protrusion of
cells in vitro.
Multilayer capsules secrete therapeutic proteins for prolong
periods of time. We quantified the secretion of therapeutic sLrig1
from 50 multilayer capsules, cultured in 96 well plates with 100 ml of
culture medium. The culture supernatant was collected and replaced
with fresh culture medium twice a week from day 14 till day 70. The
secretion of sLrig1 was detected by Western blot and quantified as
percentage of secretion of sLrig1 with respect to day 14 (figure 4c).
The secretion of sLrig1 increased exponentially till day 42, where the
highest secretion was observed. After day 42 the secretion was
relatively stable with slight fluctuations in secretion of sLrig1 until
day 70. Asmentioned above traditional 3.4% intermediate-G alginate
APA capsules showed protrusion and growth of cells in the culture
flask, therefore the secretion of sLrig1 from the APA capsules cannot
be reliably quantified. Therefore we restricted quantification of
sLrig1 from multilayer capsules.
Cell load and cell growth increases surface roughness of capsules.
Surface roughness of the capsules as a consequence of cell growth is
correlated with host responses21. We therefore questioned how
protrusion of cells influences surface roughness. To this end we
studied surface roughness of cell containing APA capsules and
multilayer capsules; APA capsules without cells were used as
control. Analysis was done on day 30 post encapsulation. As
shown in figure 5, APA capsules with cells (Rq520.84 6 15.13)
had a significant higher surface roughness compared to empty
APA capsules (Rq51.65 6 0.35) (p ,0.05). Although there was a
tendency that surface roughness of multilayer capsules with cells
(Rq511.53 6 2.82) had lower surface roughness compared to
APA capsules with cells, the difference was not statistically
significant. There was also no significant difference between
surface roughness of empty APA capsules and cell containing
Figure 1 | Cell growth leads to protrusion of cells over time. Protrusion of cells always occurs in conventional alginate-encapsulation systems.
www.nature.com/scientificreports
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multilayer capsules. In conclusion we find that cell growth and
protrusion increase the surface roughness of capsules, and this
may be ameliorated in multilayer capsules.
Discussion
The fact that mechanical strength of alginate influences cell be-
havior is based on the principle of mechanotransduction. Me-
chanotransduction is a process by which mechanical forces acting
on cells influence biochemical cell behaviour and viability22–24. This
principle of mechanotransduction was applied to design amultilayer
capsule with a minimal risk of protrusion of therapeutic cells. The
system does not involve the inclusion of toxic components or any
other molecules that might interfere with the survival of the encap-
sulated cell or with the host tissue. It is simply based on applying a
rigidity on the outside of the capsule that is not compatible with cell
survival. To our best knowledge we are the first to demonstrate this
principle in microencapsulation systems. Different cells require dif-
ferent circumstances for optimal survival18,25. For every cell type it
may be necessary to adapt the alginate with cell facilitating and
inhibitory properties. Here we used calcium-alginate because the
rigidity to kill BHK cells was already reached with this alginate-
divalent cation combination. We have also tested the efficacy of
multilayer capsules in preventing protrusion of human embryonic
kidney cells (supplementary figure 1).The rigidity however can be
further enhanced by applying divalent cations with a higher affinity
for alginates (Pb.Cu. Cd. Ba. Sr. Ca. Co. Ni. Zn.Mn.
Mg)26. Thus by using divalent cations with a higher affinity for algin-
ate such as Pb21, Cu21, Cd21, or Ba21 the rigidity can be gradually
increased27,28. Notably, application of Pb21, Cu21, and Cd21 must be
avoided because they are toxic to cells. Another effective method for
increasing alginate rigidity is increasing the G-content or increasing
the concentration of the alginate to create a mechanotransduction
environment not compatible with cell survival. The molecular pro-
cesses and sensors by which mechanotransduction occurs is still
largely unknown23,29. Recent studies have suggested that integrin’s
play a key role in mechanotransduction30,31. Since alginate lacks
integrin binding sites32, non-integrin dependent mechanotransduc-
tionmay occur whichmust be responsible for the observed effects on
cell behavior33.
Similarly different cells may require different conditions for
optimal survival in the capsule core18,25. The advantage of the multi-
layer system is that the inner capsule is not in direct contact with the
microenvironment in the host. This implies that within the multi-
layer system the balance between optimal biocompatibility in the
host and optimal cell-survival environment is less strict34–38. The
multilayer system also may improve the surface roughness as shown
in figure 5. Another issue that is overcome by the novel system is the
reported variations in PLL binding and the associated host res-
ponses21,39–41. PLL is often applied to the alginate beads in order to
reduce the pore size. Immunoprotective systems should protect the
encapsulated cells against high molecular weight effector molecules
of the adaptive immune system such as immunoglobulins and
complement factors2. The PLL capsules usually have a permeability
that allows for diffusion of molecules below 160 kDa2,42. However
binding of poly-aminoacids to alginate beads is not straightforward.
Alginate should form a superhelical core around the PLL and the PLL
itself should be forced into b-sheets40. This requires an ion exchange
process which if not correctly done leads to host responses against
Figure 2 | (a) Schematic representation of the novel multilayer capsule concept avoiding protrusion of cells. The core of multilayer capsules facilitates
growth of cells while the outer shell of the capsule traps escaping cells and induces cell death. (b) Schematic representation of methodology to
generate multilayer capsules. Briefly after coating alginate-PLL capsules, the alginate-PLL capsules are reencapsulated with growth inhibiting 2% high-G
alginate matrix. (Details in materials and methods).
www.nature.com/scientificreports
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inadequately bound PLL39,41,43,44. This is considered to be one of the
factors contributing to the low degree of reproducibility of alginate-
polyamino-acid encapsulation38,43–45. This binding is less important
when the PLL-layer can be covered with an additional layer of algin-
ate with a documented high degree of biocompatibility39,40. Therefore
the multilayer capsule procedure may contribute to reproducibility.
Moreover the high crosslinking of gelling ions in high-G alginate
reduces the pore size of multilayer capsules.
Even though the high crosslinking network obtained with high-G
alginate, results in smaller pore sizes and increases rigidity, diffusion
of nutrients and secretion of 100 kDa recombinant sLrig1 from
encapsulated cells was not obstructed in multilayer capsules. The
observed fluctuations in secretion after day 42 can be attributed to
cellular contact inhibition or deprivation of nutrients and oxygen in
the core of the capsules46. It is difficult to assess the exact concentra-
tion of sLrig1 released from the capsules. Based on antibody staining,
we can only provide a relative quantification. However the amount of
sLrig1 secreted from encapsulated BHK-sLrig1 cells depends on the
initial cell concentration and doubling time for cells. With the cur-
rent settings, we obtained approximately 17 fold increase of sLrig1
secretion per bead on day 42 with respect to day 14. In the past we
have shown 40–60% inhibition of glioma growth using 5 alginate
beads encapsulated with BHK-sLrig1 cells in mouse models9. It is
likely that the initial cell load used for encapsulation and/or number
of beads implanted can be increased to achieve higher efficacy.
It might be argued that the rigidity of 11.05 g for the 2%high-G gel
is also interfering with host-compatibility or biocompatibility by
forming a too stiff layer for host tissues in the vicinity of the capsules.
In this study however we applied only alginate-types and concentra-
tions that have already been tested in vivo in different implantation
sites including the brain47 and did not show any toxicity or severe
response in the host41,47,48. It seems that intracapsular rigidity is a
different issue than surface rigidity49,50 which previously has been
reported to be a critical issue for biocompatibility51,52.
The surface roughness of microcapsules also plays a crucial role in
host responses. A high Rq is associated with enhanced adsorption of
proteins and inflammatory cells48,51,52. Although the Rq value of APA
capsules with and without cells was not statistically significant from
the multilayer capsules with cells, we postulate that providing an
additional alginate layer may reduce the variations induced by cell
inclusions. In the present study we show that loading the systemwith
cells leads to increased surface roughness as cell free APA capsules
had a lower surface roughness than cell containing APA capsules and
multilayer capsules. This suggests that inclusion of cells affects the
gellification process. Increasing the cell load, hinders the cross link-
ing of gelling ion and as a consequence decreases mechanical
stability19. This further increases protrusion and surface roughness.
As protrusion is a random phenomenon, protrusion or disruption of
the surface structure can occur anywhere on the surface and in dif-
ferent degrees as shown by large standard deviations values in this
study. We found that APA-capsules sometimes had Rq values vary-
ing in range between 3.34 nm and 40.3 nm. Previous AFM studies
have been conducted on cell free capsules which did not report large
variations on APA capsules21. We suggest that the variation in sur-
face in cell containing capsules observed in our study may contribute
to the reported variations in host responses (biocompatibility)
against APA-encapsulated cells. Cell load13,42,53 and surface rough-
ness are interrelated and do matter for in vivo success of implanted
capsules51,52. Moreover it has been shown that the Rq of alginate
beads increases with increasing affinity of the divalent cations for
alginate51,52. By using divalent cations with a higher affinity for algin-
ate the surface roughness of alginate capsules can be gradually
increased. Therefore, to keep the surface roughness low on themulti-
layer system we recommend to use calcium ions as long as high-G
alginate is applied.
Conclusion
A system in which protrusion of cells is prevented is mandatory for
cell based therapies. In particular with encapsulated therapeutic cell
lines, outgrowth of these cells from the capsules may lead to tumor
formation. Here we report on a novel microencapsulation system
that strongly reduces cell protrusion of cells. Different types of highly
biocompatible alginates were applied to facilitate growth and survival
of therapeutic cells in the core of the capsules while destroying cells
escaping from the core of multilayer capsule. Studies are ongoing to
determine the efficacy of this system in pre-clinical models in vivo.
Methods
Alginate purification. Alginates of different compositions were obtained from ISP
Alginates Ltd UK. Two types of alginates have been purified: 1) intermediate-G
alginate (containing 44% G-chain residues, 56% M-chain residues, 23% GG-chain
residues, 21% MG-chain residues, 37% MM-chain residues) and 2) high-G alginate
(containing 67% G-chain residues, 33% M-chain residues, 54% GG-chain residues,
13%MG-chain residues, 21%MM-chain residues). Alginates were purified in-house
as described in detail elsewhere54. Briefly 12–15 gm of crude alginate was dissolved in
ice cold 1 mM Na-EGTA (ethylene glycol tetraacetic acid), under constant stirring.
The dissolved alginate was filtered through 5 mm, 1.2 mm, 0.8 mm, 0.45 mm filter
(WhatmanH, Dassel, Germany), to remove visible aggregates. Subsequently the pH of
the solution was carefully lowered to 2 with 2 N HCL 120 mM NaCl on ice.
Lowering of pH causes alginate to precipitate as alginic acid. Alginic acid precipitate
Figure 3 | Mechanical stability of alginate influences cell growth. Phase
contrast microscopic images of BHK-cell growth in 3.4% intermediate-G
alginate-poly-L-lysine (APA) capsules, and 2%high-G alginate beads. APA
capsules facilitate cell growth while 2% high-G alginate inhibited cell
growth.
www.nature.com/scientificreports
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Figure 4 | Cell growth and survival in intermediate-G alginate APA capsules and in the inner core of multilayer capsules. (a) Confocal microscope
images and quantification (n53) of live- dead encapsulated BHK cells in APA capsules and multilayer capsule after live-dead staining at different
time points. Live cells emit green fluorescence, dead cells emit red fluorescence. (b) Proof of concept of multilayer capsule: localization of live (green) and
dead (red) BHK cells in a multilayer capsule. Protruding cells are effectively killed in multilayer capsules. (c) Western blot (n53) analysis of secreted
sLrig1 protein (upper band) from BHK-sLrig1 cells encapsulated in multilayer capsules. Multilayer capsules secrete sLrig1 for prolonged periods of time.
Bovine serum albumin is visualized by nonspecific binding of secondary antibody (lower band).
www.nature.com/scientificreports
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was filtered through a Buchner funnel of pore size 1.5 mm and washed with 1 liter of
0.01N HCL 1 20 mM NaCl to remove non precipitated contaminants. Next the
proteins from the aggregate alginate acid were removed by chloroform5butanol (451
ratio) extraction. The mixture was vigorously shaken for 20 minutes. The suspended
mixture was filtered over Buchner funnel. Chloroform5butanol extraction step was
repeated twice. Subsequently the alginic acid was then bought into water by slowly
and carefully increasing the pH to 7 with 0.5 N NaOH 1 20 mMNaCl over a period
of at least 1 hr. The alginate solution obtained was further treated with
chloroform5butanol (451 ratio) to remove proteins which can only be dissolved in at
neutral pH. The mixture was centrifuged for 3 minutes at 1800 rpm, which induced
the formation of separate chloroform5butanol phase, which was removed by
aspiration. This step was repeated one more time. The last step of purification is
precipitation of alginate from alginic acid using ethanol. To each 100 ml of alginate
solution we added 200 ml absolute ethanol. Constant stirring for 10 minutes in
ethanol led to precipitate alginate. The alginate was filtered over the Buchner funnel
and washed two times with absolute ethanol. Later, the alginate was washed three
times with diethyl ether and was freeze-dried overnight. After purification 3.4% (w/v)
intermediate-G alginate and 2% (w/v) high-G alginate were dissolved at 4uC in
Krebs–Ringer–Hepes (KRH) with an appropriate osmolarity and further sterilized by
0.2 mm filtration (CorningH, NY, USA).
Mechanical stability of empty beads. Empty beads of 3.4% intermediate-G alginate
beads and 2% high-G alginate were made using air driven droplet generator using
23 g needle, gelled in 100 mM CaCl2 for 5 minutes as previously described by us19.
Mechanical stability of alginate capsule can be quantified using different methods like
burst pressure55, ultrasound56, Young’s modulus57, however we prefer to calculate the
mechanical stability based on force and time required to resist compression19. The
mechanical stability was quantified with a Texture Analyzer XT plus (Stable Micro
Systems, Godalming, UK) equippedwith a force transducerwith a resolution of 1 mN
as previously described by us19. Texture Exponent software version 6.0 was used for
analyzing the data. Briefly individual beads of size 500 mmmicrometer were carefully
sorted using a dissection microscope (Leica MZ75 microsystems) equipped with an
ocular micrometer with an accuracy of 25 mm. Individual beads were carefully placed
on plate, storage solution was carefully removed. The mechanical stability of beads
was measured by compressing individual microcapsules to 60% using P/25L mobile
probe with a pretest speed of 0.5 mm/sec, a test speed of 0.01 mm/sec, and a posttest
speed of 2 mm/sec. The trigger force was set to 2 grams. The force exerted by the
probe to compress the bead was recorded as function of time.
Cell microencapsulation. Baby hamster kidney (BHK) cells expressing anti-tumor
protein sLrig1 (soluble leucine rich repeats and immunoglobulin like domain1) a
negative regulator of growth factor signaling9 were grown in DMEM medium
supplemented with 4.5 g/L glucose, 10% (v/v) fetal bovine serum (compliment
deactivation), 1% (v/v) Antibiotic-Antimycotic (100X) (Sigma-Aldrich,). BHK
control and BHK-sLrig1expressing cells at concentrations of 6 3 106 cells per
milliliter of sterile 3.4% intermediate-G alginate or 2% high-G alginate were carefully
mixed and were transferred into droplets with an electrostatic bead generator, using a
27 g needle. The droplets were collected in 100 mM CaCl2 as gelling solution for 5
minutes. Subsequently, intermediate-G alginate beads were incubated with sterile
(0.2 mm filtered) 0.05% poly-L- lysine (PLL) (poly-L-lysine-HCl,Mw 22 kDa, Sigma-
Aldrich, The Netherlands) for a period of 3 minutes on ice and 4 minutes at room
temperature. PLL coated capsules were subsequently incubated with 0.34%
intermediate-G alginate in calcium-free KRH solution with an osmolarity of 310 to
form alginate-poly-L-lysine alginate (APA) capsule. Next the cell-containing
Figure 5 | Cell load, cell growth and alginate type affect surface roughness of the capsule. Surface roughness (Rq) of intermediate-G alginate-PLL-
alginate (APA) capsules without cells, with cells and in multilayer capsule with cells on day 30 post encapsulation (n54). Cell load increases the surface
roughness of capsules. Multilayer capsules with cells show a tendency towards lower surface roughness than APA capsules with cells. Values are expressed
as mean 6 SD, *p,0.05.
www.nature.com/scientificreports
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intermediate-G alginate-PLL membrane was suspended in a 2% high-G alginate
solution. After careful mixing the solution was brought in another type of
droplet-generator using a 23 g needle and 100 mMCaCl2 as gelling solution58,59. This
step is meant to form multilayer capsules. A schematic workflow of making the
multilayer capsules is shown in figure 2b. The encapsulated cells were subsequently
cultured in 25 cm2 culture flasks containing 5 ml growth medium (Dulbecco’s
Modified Eagle’s culture medium (DMEM) supplemented with 4.5 g/L glucose, 10%
(v/v) fetal bovine serum (compliment deactivation), Antibiotic-Antimycotic (100X)
1% (v/v) Sigma-Aldrich,) and kept in a standard tissue culture incubator with 5%
CO2, at 37uC. Medium was changed thrice a week. The diameters of the beads and
capsules were measured with a dissection microscope (Leica MZ75 microsystems)
equipped with an ocular micrometer with an accuracy of 25 mm. The 2% high-G
alginate beads and APA capsules had diameter of 250–350 mm while the final
multilayer capsules had a diameter of 550–650 mm.
Viability and live-dead quantification of encapsulated cells. Viability of BHK-
sLrig1 cells encapsulated in APA capsules and multilayer capsules was studied with a
live-dead staining kit of Invitrogen (Calcein AM (4 mM), Ethidium homodimer-1
(2 mM)). Cell containing capsules were washed three times with KRH solution
containing 2.5 mM CaCl2. Capsules were incubated in the dark for 30 minutes in
2 ml of serum free medium containing 1 ml of calcein AM and 2 ml of ethidium
homodimer-1. Subsequently capsules were washed five times with KRH solution
containing 2.5 mM CaCl2. Stained cells in capsules were visualized by a Leica TCS
SP2 AOBS confocal microscope and objective HC PL APO CS 10x/0.30 dry, 11 mm.
An Argon laser was used for excitation of calcein AM and the emission light over
505 nm and 530 nm was measured for live cells. A Helium Neon 543 nm laser was
used for excitation of ethidium homodimer-1 and the emission light over 650 nm
detected for dead cells. The pictures of sections were taken through entire Z-axis
through the capsules. Imaris (R) x64 version 7.6.4 software was used to process the
raw data to construct 3D images and quantify live-dead cells. Viability and live-dead
quantification of cells in capsules was determined on day 1, 7, 14, 21, 28, 35, 49, 56, 63,
and 70.
Quantification and detection of sLrig1.To quantify the relative secretion of sLrig1
protein from multilayer capsules we carefully sorted 50 multilayer capsules using a
dissection microscope (Leica MZ75 microsystems) The 50 individually sorted
capsules were placed in 96 well plates and cultured in 100 ml of growth media.
Culture supernatants were collected twice a week between day 14 - day 70 by
replacing with fresh 100 ml of growth media. Quantification and detection of
secreted sLrig1 was done by western blot using goat anti flag monoclonal
antibody. Culture supernatant from encapsulated BHK control cells was used as
negative control, whereas conditioned media from monolayer BHK-sLrig1 was
used as positive control. From day 14 onwards, the volume of the cell culture
media was doubled (100 ml to 200 ml) because of increase in cell growth in the
capsules. Therefore the volume loaded on the gels was also doubled (to
compensate for the 2x dilution). Briefly, 4 ml of culture supernatant of day 14 and
8 ml of culture supernatant from day 21 to day 70 from encapsulated cells were
mixed in 151 ratio with 1x loading buffer (Invitrogen, Belgium) and resolved on
4–12% NuPAGEH Novex 4–12% Bis-Tris Gel (Invitrogen, Belgium) and
transferred to polyvinylidene fluoride (PVDF) membranes (Invitrolon, Invitrogen,
Belgium). ECL AdvanceTM blocking agent 2% (w/v) (GE Healthcare, UK) in Tris-
buffered saline containing 0.1% Triton X-100 (TBST) was used for blocking PVDF
membrane for at least 2 hours. Goat anti-FLAG mouse monoclonal antibody
(1550000) (Sigma, F1804) was used as primary antibody for the detection of
recombinant FLAG-tagged sLrig1. Primary antibody was incubated overnight at
4uC. HRP-conjugated goat anti-mouse antibody (Jackson ImmunoResearch, 115-
036-003) was used as secondary antibody (15150000). The signal was visualized
using an ECLTM Advance Western blot detection kit (GE Healthcare, UK). Bovine
serum albumin (BSA) was used as housekeeping protein to confirm sample equal
loading’’. BSA is visualized by nonspecific binding of secondary antibody. ECL
image acquisition was performed with an ImageQuant LAS4010 imaging station
and signals were quantified with Image Quant TL software (GE Healthcare,
Belgium). Data was expressed as a relative percentage of the secretion at day 14.
Surface roughness of capsules. Surface roughness of different area of microcapsules
was determined by atomic force microscopy (AFM). APA capsules without cells were
used as control. Surface roughness of empty APA capsules (n54), APA capsules
(n54) and multilayer capsules (n54) with cells was studied on day 30 post-
encapsulation using a Bruker dimensions 3100 atomic force microscopy.
Topographic imaging of capsules was performed at room temperature using the
tapping mode21,60. Briefly single capsules were carefully sorted using a dissection
microscope (Leica MZ75 microsystems), washed with demineralized water and
placed onmicroscopic slides. The excess of water was carefully aspirated. The surface
of the microcapsules was scanned by the tip of a silicon nitride cantilever
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